When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study

ObjectivesTo compare the response to highly active antiretroviral therapy (HAART) in individuals starting HAART at different CD4 cell counts. DesignThe mean increase in CD4 cell count and rate of virological failure after commencing HAART were measured in antiretroviral-naive patients (1421) in a large, non-randomized multicentre, observational study in Italy (ICONA). Clinical endpoints were also evaluated in a subset of patients who started HAART with a very low CD4 cell count. ResultsAfter 96 weeks of therapy, the mean rise in CD4 cell count was 280, 281 and 186 × 106 cells/l in patients starting HAART with a CD4 cell count < 200, 201–350 and > 350 × 106 cells/l, respectively. Patients starting HAART with a CD4 cell count < 200 × 106 cells/l tended to have a higher risk of subsequent virological failure [relative hazard (RH), 1.15; 95% confidence interval (CI), 0.93–1.42] compared with patients starting with > 350 × 106 cells/l. There was no difference in risk between the 201–350 and the > 350 × 106 cells/l groups (RH, 1.0; 95% CI, 0.79–1.29). The incidence of new AIDS-defining diseases/death in patients who started HAART with a CD4 count < 50 was 0.03/person-year (95% CI, 0.10–0.33) during the time in which the patient's CD4 cell count had been raised to > 200 × 106 cells/l. ConclusionsThere was no clear immunological or virological advantage in starting HAART at a CD4 cell count > 350 rather than at 200–350 × 106 cells/l. The increase in CD4 cells restored by HAART is meaningful in that they are associated with reduced risk of disease/death.

[1]  B. Walker,et al.  Treat HIV-1 infection like other infections--treat it. , 1998, JAMA.

[2]  D. Cooper,et al.  A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome , 2000, AIDS.

[3]  Douglas D. Richman,et al.  HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function , 2000, The Journal of experimental medicine.

[4]  D. Ho,et al.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.

[5]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[6]  M. Feinberg.  Hidden dangers of incompletely suppressive antiretroviral therapy , 1997, The Lancet.

[7]  C. A. Macken,et al.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.

[8]  M. Moroni,et al.  Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.

[9]  S. Bonhoeffer.  Models of viral kinetics and drug resistance in HIV-1 infection. , 1998, AIDS patient care and STDs.

[10]  D. Ho,et al.  Time to hit HIV, early and hard. , 1995, The New England journal of medicine.

[11]  Giovanni Rezza,et al.  HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion , 1994, BMJ.

[12]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.

[13]  B. Gallagher,et al.  Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. , 2000, The New England journal of medicine.

[14]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[15]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[16]  M Egger,et al.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. , 1999, JAMA.

[17]  A. Telenti,et al.  Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. , 1999, Journal of acquired immune deficiency syndromes.

[18]  D. Costagliola,et al.  Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor , 2000, AIDS.

[19]  R. Reves,et al.  The case for conservative management of early HIV disease. , 1998, JAMA.

[20]  C. Sabin,et al.  Risk of new AIDS diseases in people on triple therapy , 1999, The Lancet.

[21]  C. Sabin,et al.  CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. , 1999, The Journal of infectious diseases.

[22]  Richard A. Loftus,et al.  HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.

[23]  W. S. Clark,et al.  Clinical Comparison of an Enhanced-Sensitivity Branched-DNA Assay and Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma , 1998, Journal of Clinical Microbiology.